Table of contents:

1. Introduction
2. Information collection process
3. Methodological note
4. Information required by Article 5b(2) of the Regulation
4.1 Nature, number and scale of incidents showing health and social problems in which the new psychoactive substance may potentially be involved, and the patterns of use of the new psychoactive substance (Article 5b(2a))
4.2 Chemical and physical description of the new psychoactive substance and the methods and precursors used for its manufacture or extraction (Article 5b2(b))
4.3 Pharmacological and toxicological description of the new psychoactive substance (Article 5b2(c))
4.4 Involvement of criminal groups in the manufacture or distribution of the new psychoactive substance (Article 5b2(d))
4.5 Information on the human and veterinary medical use of the new psychoactive substance, including as an active substance in a medicinal product for human use or in a veterinary medicinal product
4.6 Information on the commercial and industrial use of the new psychoactive substance, the extent of such use, as well as its use for scientific research and development purposes
4.7 Information on whether the new psychoactive substance is subject to any restrictive measures in the Member States
4.8 Information on whether the new psychoactive substance is currently or has been under assessment within the system established by the 1961 Single Convention on Narcotic Drugs, as amended by the 1972 Protocol, and the 1971 Convention on Psychotropic Substances
4.9 Other relevant information
5. Analysis and assessment
6. Reference